Last-Resort access to eltrombopag for patients with low platelet counts
NCT ID NCT04837703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers eltrombopag to patients with serious or life-threatening thrombocytopenia (low platelet counts) who have no other treatment options and cannot join a clinical trial. A licensed physician must request the drug, and the potential benefit must outweigh the risks. The goal is to control the disease by raising platelet levels, not to cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Cord blood cells aim to speed platelet recovery in transplant patients
- Platelet transfusions may influence blood vessel health in critically ill patients
- New drug strategy may reduce blood transfusions after organ transplants
- Blood test could predict bleeding risk in cancer patients
- New study tests rapid blood test to prevent bleeding emergencies in pregnancy